Literature DB >> 686708

Pharmacokinetics of netilmicin in the presence of normal or impaired renal function.

G Humbert, A Leroy, J P Fillastre, G Oksenhendler.   

Abstract

A pharmacokinetic study of netilmicin was conducted in 12 healthy subjects and 24 subjects with chronic renal failure. After intramuscular administrations of 2 and 3 mg of netilmicin per kg in normal subjects, the mean peak serum concentrations were 5.46 and 8.83 mug/ml, respectively. After intravenous infusions of identical doses, the mean maximum serum levels, occurring at the end of the infusion, were 11.79 and 15.75 mug/ml, respectively. The pharmacokinetic data were very similar via the two routes of administration and for the two doses. The elimination half-life was 2.20 h, and 80 to 90% of the injected dose was recovered in urine during the first 24 h. After intramuscular administration of 2 mg/kg in subjects with chronic renal impairment, the elimination half-life increased to 29.48 h, and urinary elimination was inversely related to the degree of impairment. A study was conducted throughout hemodialysis sessions: serum concentrations decreased by 63.3%. The linear relationships between the elimination rate constant and creatinine clearance and the elimination half-life and serum creatinine allowed us to establish dosage schedules according to the degree of renal failure.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 686708      PMCID: PMC352402          DOI: 10.1128/AAC.14.1.40

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Calculation of drug dosage regimens in patients with renal disease: a new nomographic method.

Authors:  P Spring
Journal:  Int J Clin Pharmacol Biopharm       Date:  1975-01

2.  [Practical modifications concerning the determination of antibiotics in clinical practice].

Authors:  Y CHABBERT; H BOULINGRE
Journal:  Rev Fr Etud Clin Biol       Date:  1957-06

3.  Comparative pharmacokinetics of lividomycin, amikacin and sisomicin in normal subjects and in uraemic patients.

Authors:  A Leroy; G Humbert; G Oksenhendler; J P Fillastre
Journal:  J Antimicrob Chemother       Date:  1976-12       Impact factor: 5.790

4.  Pharmacokinetic study of netilmicin.

Authors:  B R Meyers; S Z Hirschman; G Wormser; D Siegel
Journal:  Antimicrob Agents Chemother       Date:  1977-07       Impact factor: 5.191

5.  Clinical pharmacology of netilmicin.

Authors:  B S Yap; D Stewart; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1977-12       Impact factor: 5.191

6.  Gentamicin pharmacokinetics during hemodialysis.

Authors:  T G Christopher; D Korn; A D Blair; A W Forrey; M A O'Neill; R E Cutler
Journal:  Kidney Int       Date:  1974-07       Impact factor: 10.612

7.  Comparative nephrotoxicities of netilmicin and gentamicin in rats.

Authors:  F C Luft; M N Yum; S A Kleit
Journal:  Antimicrob Agents Chemother       Date:  1976-11       Impact factor: 5.191

8.  In vitro comparison of netilmicin, a semisynthetic derivative of sisomicin, and four other aminoglycoside antibiotics.

Authors:  S A Kabins; C Nathan; S Cohen
Journal:  Antimicrob Agents Chemother       Date:  1976-07       Impact factor: 5.191

9.  Bactericidal efficacy of Sch 20569 and amikacin against gentamicin-sensitive and -resistant organisms.

Authors:  J J Rahal; M S Simberkoff; K Kagan; N H Moldover
Journal:  Antimicrob Agents Chemother       Date:  1976-04       Impact factor: 5.191

10.  Netilmicin and gentamicin: comparative pharmacology in humans.

Authors:  L J Riff; G Moreschi
Journal:  Antimicrob Agents Chemother       Date:  1977-04       Impact factor: 5.191

  10 in total
  13 in total

1.  Dosing Recommendations for Continuous Venovenous Hemodiafiltration with AN69 Filter Membranes and Prismaflex Dialyzers.

Authors:  Eugenia Yeh; Glen Brown
Journal:  Can J Hosp Pharm       Date:  2009-11

Review 2.  Clinical pharmacokinetics of aminoglycoside antibiotics.

Authors:  J C Pechere; R Dugal
Journal:  Clin Pharmacokinet       Date:  1979 May-Jun       Impact factor: 6.447

3.  Pharmacokinetics and metabolism of 14C-isepamicin in humans following intravenous administration.

Authors:  C Lin; C Korduba; M Affrime; E Radwanski; A Nomeir; V Batra; D Cutler; M N Cayen
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191

4.  Prospective comparative study of efficacy and toxicity of netilmicin and amikacin.

Authors:  B V Bock; P H Edelstein; R D Meyer
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

5.  Tentative interpretive criteria for the diffusion susceptibility test using 30-microgram netilmicin disks.

Authors:  R N Jones; A L Barry; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

Review 6.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

Review 7.  Nonparametric meta-analysis of published data on kidney-function dependence of pharmacokinetic parameters for the aminoglycoside netilmicin.

Authors:  F Keller; K Erdmann; M Giehl; P Buettner
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

8.  Pharmacokinetic assessment of netilmicin in newborns and older children.

Authors:  T Bergan; H Michalsen
Journal:  Infection       Date:  1982       Impact factor: 3.553

9.  Population pharmacokinetics of netilmicin in short-term prophylactic treatment.

Authors:  Nerea Jauregizar; Jeff A Wald; Ander Astobieta; Jose M Rodriguez Sasiain; John C Lukas; Rosario Calvo
Journal:  Br J Clin Pharmacol       Date:  2003-06       Impact factor: 4.335

10.  Once-daily versus thrice-daily administration of netilmicin in combination therapy of Pseudomonas aeruginosa infection in a man-adapted neutropenic animal model.

Authors:  A U Gerber; S Kozak; C Segessenmann; U Flückiger; T Bangerter; U Greter
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-03       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.